Why big pharma is turning to biological meds

Why big pharma is turning to biological meds: Biological meds are increasingly being seen as more lucrative to pharma companies than the standard chemical kinds. While chemical drugs are based on small, stable molecules (and have been used since the industry emerged), their biological counterparts are based on much larger and more volatile proteins. Despite their lack of stability, biologics-based drugs have recently become more appealing to big pharma companies as they use our own DNA to cure us, making them more effective than chemical meds in treating genetic diseases such as diabetes and cancer, the Wall Street Journal’s Preetika Rana explains (runtime 2:53).